Lead Product(s): Anti-Corona (COVID-19) IgG product
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2020
Kamada plans to initiate the development of an Anti-Corona polyclonal immunoglobulin using its proprietary plasma derived IgG platform technology for severely ill coronavirus patients.